Big Pharma, which is under attack in the U.S. for its pricing and patent policies, has gone on the offensive overseas. It has asked the U.S. Trade Representative’s Office to place India and 12 other countries on the priority watch list in its 2016 Special 301 report, which identifies countries the U.S. believes do not adequately protect intellectual property rights.
The Pharmaceutical Research and Manufacturers of America (PhRMA), a group that represents leading pharma and biotech companies in the U.S., was particularly critical of India in comments it submitted this week to the USTR in advance of a March hearing regarding trade issues and the Special 301 report.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
